Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.
For the treatment of pneumonia due to Pneumocystis carinii.
Fisons Corp, Rochester, New York, United States
Community Consortium of San Francisco, San Francisco, California, United States
Denver CPCRA / Denver Public Hlth, Denver, Colorado, United States
Wilmington Hosp / Med Ctr of Delaware, Wilmington, Delaware, United States
Harvard (Massachusetts Gen Hosp), Boston, Massachusetts, United States
Julio Arroyo, West Columbia, South Carolina, United States
Bronx Municipal Hosp Ctr/Jacobi Med Ctr, Bronx, New York, United States
UCLA-Los Angeles/Brazil AIDS Consortium (LABAC) CRS, Los Angeles, California, United States
Childrens Hosp. LA - Dept. of Ped., Div. of Clinical Immunology & Allergy, Los Angeles, California, United States
Children's Hosp. & Research Ctr. Oakland, Ped. Clinical Research Ctr. & Research Lab., Oakland, California, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.